Therefore, the GLUT1-targeting, GSH reductive sensitive PAMAM–CPT conjugate can be served as an attractive platform for on demand, anticancer drug delivery, and it is a promising novel nanomedicine for liver cancer treatment. The gene discussed is SLC2A1; the disease is liver cancer.